207 related articles for article (PubMed ID: 30679796)
21. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
23. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
Cain JA; Xiang Z; O'Neal J; Kreisel F; Colson A; Luo H; Hennighausen L; Tomasson MH
Blood; 2007 May; 109(9):3906-14. PubMed ID: 17218386
[TBL] [Abstract][Full Text] [Related]
24. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.
Sexl V; Piekorz R; Moriggl R; Rohrer J; Brown MP; Bunting KD; Rothammer K; Roussel MF; Ihle JN
Blood; 2000 Sep; 96(6):2277-83. PubMed ID: 10979977
[TBL] [Abstract][Full Text] [Related]
25. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
26. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
27. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
[TBL] [Abstract][Full Text] [Related]
28. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
30. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.
Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B
Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176
[TBL] [Abstract][Full Text] [Related]
31. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
32. Grb10 is involved in BCR-ABL-positive leukemia in mice.
Illert AL; Albers C; Kreutmair S; Leischner H; Peschel C; Miething C; Duyster J
Leukemia; 2015 Apr; 29(4):858-68. PubMed ID: 25249015
[TBL] [Abstract][Full Text] [Related]
33. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
34. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
35. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
36. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Wang Y; Cai D; Brendel C; Barett C; Erben P; Manley PW; Hochhaus A; Neubauer A; Burchert A
Blood; 2007 Mar; 109(5):2147-55. PubMed ID: 17090651
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.
Berger A; Sexl V; Valent P; Moriggl R
Oncotarget; 2014 Oct; 5(20):9564-76. PubMed ID: 25333255
[TBL] [Abstract][Full Text] [Related]
39. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]